Capricorn Fund Managers Ltd Invests $144,000 in MediciNova, Inc. (NASDAQ:MNOV)

Capricorn Fund Managers Ltd bought a new position in shares of MediciNova, Inc. (NASDAQ:MNOVGet Rating) in the fourth quarter, Holdings Channel reports. The fund bought 53,700 shares of the biopharmaceutical company’s stock, valued at approximately $144,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in MediciNova in the first quarter valued at about $54,000. Buckingham Strategic Partners bought a new stake in shares of MediciNova during the fourth quarter worth about $27,000. Qube Research & Technologies Ltd bought a new stake in shares of MediciNova during the fourth quarter worth about $37,000. UBS Group AG grew its holdings in shares of MediciNova by 96.0% during the third quarter. UBS Group AG now owns 19,272 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 9,437 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of MediciNova by 132.3% during the third quarter. Dimensional Fund Advisors LP now owns 54,532 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 31,062 shares during the last quarter. 15.57% of the stock is owned by institutional investors.

Separately, StockNews.com began coverage on MediciNova in a report on Tuesday. They issued a “hold” rating on the stock.

Shares of NASDAQ:MNOV traded up $0.01 during trading on Wednesday, reaching $2.39. 111,275 shares of the stock were exchanged, compared to its average volume of 80,824. The stock has a fifty day moving average of $2.67 and a two-hundred day moving average of $2.71. MediciNova, Inc. has a 1-year low of $2.09 and a 1-year high of $5.09.

MediciNova (NASDAQ:MNOVGet Rating) last posted its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. Equities research analysts anticipate that MediciNova, Inc. will post -0.27 earnings per share for the current fiscal year.

About MediciNova (Get Rating)

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.

Recommended Stories

Want to see what other hedge funds are holding MNOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediciNova, Inc. (NASDAQ:MNOVGet Rating).

Institutional Ownership by Quarter for MediciNova (NASDAQ:MNOV)

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.